NCT00990080已完成3 期
Safety and Immunogenicity of Two Mixed Primary Immunization Schedules: Pediacel® at 2 and 4 Months of Age Followed by One Dose of Infanrix™ IPV/Hib at 6 Months of Age; and, Infanrix™ IPV/Hib at 2 Months of Age, Followed by Pediacel® at 4 and 6 Months of Age
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 253
- 试验地点
- 2
- 主要终点
- Descriptive statistics will be used to summarize the safety and immunogenicity of the two mixed primary immunization schedules.
研究概览
简要总结
To demonstrate the safety and immunogenicity of two mixed primary immunization schedules: Pediacel® at 2 and 4 months of age followed by one dose of Infanrix™ IPV/Hib at 6 months of age; and, Infanrix™ IPV/Hib at 2 months of age, followed by Pediacel® at 4 and 6 months of age.
详细描述
Immunogenicity will be evaluated using the following:
Serological outcome measures will be assessed on day 0 (visit 1) and 28-42 days after the 3rd dose of the primary series for both groups:
- Seroprotection rates for antibodies against PRP (anti-PRP), defined as percentage of subjects with antibody concentrations ≥ 0.15 µg/ml and ≥ 1.0 µg/ml.
- Geometric mean concentration (GMC) for antibodies against PT, FHA, PRN, and FIM.
- Anti-pertussis antibody concentrations ≥4-fold rise (post-Dose 3/pre-Dose 1).
Safety will be evaluated using the following:
- Occurrence, time to onset, number of days of occurrence, severity and seriousness of solicited injection site reactions (tenderness, erythema, swelling) and systemic symptoms (fever, vomiting, crying abnormal, drowsiness, appetite decreased, irritability) within 8 days (Day 0 - Day 7) after each vaccination and across all vaccinations.
- Occurrence, nature, time to onset, duration, severity, and relationship to vaccination of unsolicited adverse events (AE) occurring within 31 days (Day 0 -Day 30) of each vaccination.
- Occurrence, nature, time to onset, duration, and relationship to vaccination of any serious adverse events (SAE) during the entire study period for all groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 42 Days 至 3 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Infants aged 6 wks (42 days) to 2 months (1 day before they turn 3 months) inclusive on the day of inclusion.
- •Born at full term of pregnancy (defined as ≥37 weeks, 0 days).
- •Informed consent form signed by the parent(s) or legally authorized representative.
- •Able to attend all scheduled visits and to comply with the study procedures.
- •Parent or legally authorized representative has access to a telephone.
- •Parent or legally authorized representative able to read and write in English or French.
排除标准
- •Participation in another clinical trial in the 4 weeks preceding the first trial vaccination.
- •Planned participation in another clinical trial during the present trial period.
- •Personal history of congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy.
- •Known or suspected systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing the same substances as the trial vaccine(s).
- •Chronic illness that could interfere with trial conduct or completion.
- •Received blood or blood-derived products since birth.
- •Any vaccination preceding the first trial vaccination, except vaccinations recommended as part of the infant schedule.
- •Previous vaccination with any acellular pertussis- (DTaP) or whole cell pertussis-DTwP) based combination vaccines, Haemophilus influenzae type b Hib)conjugate,or poliovirus vaccines.
- •Coagulation disorder contraindicating intramuscular vaccination.
- •Clinically significant findings on review of systems (determined by investigator or sub-investigator to be sufficient for exclusion).
- •Developmental delay or neurological disorder.
- •Any condition which, in the opinion of the investigator, would interfere with the evaluation of the vaccine or pose a health risk to the subject.
- •History of Hib, diphtheria, tetanus, pertussis or poliovirus disease.
研究组 & 干预措施
Group 1
Active Comparator
Pediacel® at 2 and 4 months of age followed by Infanrix™-IPV/Hib at 6 months.
干预措施: Pediacel® and Infanrix™-IPV/Hib (Biological)
Group 2
Active Comparator
Infanrix™-IPV/Hib at 2 months of age followed by Pediacel® at 4 and 6 months.
干预措施: Pediacel® and Infanrix™-IPV/Hib (Biological)
结局指标
主要结局
Descriptive statistics will be used to summarize the safety and immunogenicity of the two mixed primary immunization schedules.
时间窗: serology at 2 and 7 months of age
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.HIV InfectionsNCT00001044National Institute of Allergy and Infectious Diseases (NIAID)80
已完成
2 期
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young AdultsInvasive Meningococcal DiseaseNCT01272180Novartis Vaccines484
已完成
4 期
The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza VaccineSeasonal InfluenzaHand, Foot and Mouth DiseaseNCT04133584Zhejiang Provincial Center for Disease Control and Prevention1,134
已完成
4 期
Phase IV Interchangeability Study of a Liquid Pentavalent Combination VaccineHaemophilus Influenzae Type BTetanusDiphtheriaPertussisHepatitis BNCT00674908Shantha Biotechnics Limited144
进行中（未招募）
2 期
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy AdolescentsMeningitis, MeningococcalNCT05087056GlaxoSmithKline312